<DOC>
	<DOCNO>NCT02744339</DOCNO>
	<brief_summary>The primary objective study • Assess pharmacodynamic profile riociguat subject symptomatic pulmonary hypertension heart failure preserve ejection fraction The secondary objective study - Assess safety tolerability riociguat study population - Assess change dimension leave right ventricle cardiac function parameter use cardiac magnetic resonance imaging</brief_summary>
	<brief_title>Pharmacodynamic Effects Riociguat Pulmonary Hypertension Heart Failure With Preserved Ejection Fraction</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<criteria>18 &lt; 80 year age time inform consent ( The low age limit may higher legally require participate country . ) Male female subject symptomatic PH HFPEF ( group 2 / 2.2 Dana Point classification ( 4 ) WHO class II IV ) ( Other group PH , especially HFREF , PAH , CTEPH , must rule accord accepted diagnostic procedure guideline , see section 5.1.2 Exclusion criterion . ) PHHFPEF define : LVEF ≥50 % , diagnose echocardiography leave heart catheterization ( LHC ) within 30 day randomization PAPmean ≥25 mmHg rest , measure RHC PAWP &gt; 15 mmHg rest , measure RHC Optimized therapy hypertension The dose regimen background treatment must stable &gt; 30 day randomization . Diuretic therapy must stable ≥1 week . RHC result definite diagnosis PH old 12 week Visit 1 . RHC must perform participate center standardized condition CMRI must perform Visit 1 ( baseline ) must older 12 week parameter measure listed Section 7.3.3 Women eligible childbearing potential , define : Postmenopausal woman ( i.e . last menstrual bleeding least 2 year randomization ) Women bilateral tubal ligation Women bilateral ovariectomy Women hysterectomy , childbearing potential , woman eligible A serum pregnancy test negative prestudy visit , The woman use combination condom safe highly effective contraception method ( hormonal contraception implant combine oral contraceptive , certain intrauterine device ) entire duration study . Able understand follow instruction participate study entire duration Written inform consent PH group group 2.2 accord Dana Point classification . ( 4 ) In particular , PAH , CTEPH , HFREF must rule accord accepted diagnostic procedure guideline . Cardiac decompensation , hospitalization visit emergency department , ≤30 day randomization Left heart disease ischemic heart disease dilate cardiomyopathy Resynchronization therapy time Need intravenous ( IV ) diuretic ≤30 day randomization Treatment inotropes IV vasodilator ≤30 day randomization Pretreatment endothelin receptor antagonist ( ERAs ) , phosphodiesterase type 5 ( PDE5 ) inhibitor , prostanoids ≤30 day randomization , nitrate ≤7 day randomization Subjects medically require treatment drug line exclusion criterion study prohibit concomitant medication ( see section 6.9 ) study Bronchial asthma chronic obstructive pulmonary disease ( COPD ) force expiratory volume 1 second ( FEV1 ) &lt; 60 % predict Restrictive lung disease total lung capacity ( TLC ) &lt; 60 % predicted Subjects oxygen therapy Severe congenital abnormality lung , thorax , diaphragm Clinically relevant hepatic dysfunction show : Aspartate aminotransferase ( AST ) ≥3 time upper limit normal ( ULN ) Child Pugh stage B C cirrhotic subject Severe renal impairment ( glomerular filtration rate [ GFR ] &lt; 30mL/min/1.73 m2 calculate Modification Diet Renal Disease [ MDRD ] formula ) Uncontrolled arterial hypertension ( SBP &gt; 180 mmHg diastolic blood pressure [ DBP ] &gt; 110 mmHg ) SBP &lt; 110 mmHg baseline Myocardial disease , ischemic dilative infiltrative myocardial disease ( i.e . amyloidosis , hypertrophic cardiomyopathy ) Severe aortic mitral stenosis , stenosis indication surgery Coronary artery disease angina Canadian Cardiovascular Society ( CCS ) class III IV require nitrate , unstable angina , acute myocardial infarction &lt; 90 day randomization Reperfusion procedure ( percutaneous coronary intervention [ PCI ] coronary artery bypass graft [ CABG ] ) &lt; 90 day randomization , &lt; 21 day case negative stress test effect PCI Stroke persistent neurological deficit Subjects positive human immunodeficiency virus ( HIV ) Resting HR awake &lt; 50 beat per minute ( BPM ) &gt; 105 BPM ( case atrial fibrillation &gt; 110 BPM ) Participation another clinical study &lt; 90 day randomization Subjects medical disorder , condition , history thereof opinion investigator would impair subject 's ability participate complete 26week study Subjects underlie medical disorder anticipate life expectancy 2 year noncardiac disease ( e.g . active cancer disease localize / metastasize tumor mass ) Subjects history multiple drug allergy Subjects hypersensitivity investigational drug excipients Previous assignment treatment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>PH-HFpEF</keyword>
</DOC>